The HARM registry (HCV patients treatment) is focused on the collection of data on patients with chronic hepatitis C who have been treated with direct-acting antivirals (DAAs). Over the last few years, antiviral treatment of patients with chronic hepatitis C has been increasingly used in the Czech Republic. This treatment involves DAAs either in combination with pegylated interferon alpha or ribavirin, or standalone as part of an IFN-free treatment. Treatment with DAAs is expensive and its availability is limited; therefore, it is necessary to obtain summary information on this type of treatment in the Czech Republic. Prof Petr Urbanek, MD, PhD, President of the Czech Society of Hepatology, initiated the development of a non-commercial research database, which will gather data on this treatment. Development of this database was also supported by the Czech Society for Infectious Diseases. Centres for the treatment of viral hepatitis C, as listed in the Protocol and defined by the Czech Society of Hepatology and the Czech Society for Infectious Diseases, will be involved in the project.

The registry will involve records on all patients who have been diagnosed with viral hepatitis C and who have been treated with DAAs or with standard therapy starting from 2016.

Primary objectives of the project:

• to collect epidemiological and clinical data on patients with chronic HCV infection who have been treated with DAAs or with standard therapy,
• to assess data on treatment of HCV patients.

Secondary objective of the project:

• to evaluate data on patients’ treatment response.